Disease characteristics in a population-based cohort of 82 102 individuals with breast cancer diagnosed between 2008 and 2019
| > . | No SSI n = 69 227 . | SSI n = 12 875 . | Overall n = 82 102 . |
|---|---|---|---|
| Invasivity | |||
| Invasive | 61 589 (89.0) | 11 724 (91.1) | 73 313 (89.3) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 180 (0.3) | 39 (0.3) | 219 (0.3) |
| Tumour stage | |||
| T0 | 423 (0.6) | 72 (0.6) | 495 (0.6) |
| Tis | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| T1 | 39 075 (56.5) | 6313 (49.0) | 45 388 (55.3) |
| T2 | 18 137 (26.2) | 4266 (33.1) | 22 403 (27.3) |
| T3 | 2809 (4.1) | 782 (6.1) | 3591 (4.4) |
| T4 | 473 (0.7) | 151 (1.2) | 624 (0.8) |
| Unknown | 849 (1.2) | 179 (1.4) | 1028 (1.3) |
| Histological tumour type | |||
| NST | 47 159 (68.1) | 9012 (70.0) | 56 171 (68.4) |
| NST + lobular | 1250 (1.8) | 292 (2.3) | 1542 (1.9) |
| Lobular | 7803 (11.3) | 1575 (12.2) | 9378 (11.4) |
| Other invasive | 4500 (6.5) | 676 (5.3) | 5176 (6.3) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 1057 (1.5) | 208 (1.6) | 1265 (1.5) |
| NHG | |||
| 1 | 12 478 (18.0) | 1704 (13.2) | 14 182 (17.3) |
| 2 | 29 363 (42.4) | 5450 (42.3) | 34 813 (42.4) |
| 3 | 15 889 (23.0) | 3590 (27.9) | 19 479 (23.7) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 4039 (5.8) | 1019 (7.9) | 5058 (6.2) |
| ER | |||
| Positive | 52 522 (75.9) | 9743 (75.7) | 62 265 (75.8) |
| Negative | 8190 (11.8) | 1813 (14.1) | 10 003 (12.2) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 1057 (1.5) | 207 (1.6) | 1264 (1.5) |
| PR | |||
| Positive | 44 385 (64.1) | 8136 (63.2) | 52 521 (64.0) |
| Negative | 16 256 (23.5) | 3407 (26.5) | 19 663 (24.0) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 1128 (1.6) | 220 (1.7) | 1348 (1.6) |
| HER2 | |||
| Positive | 7701 (11.1) | 1832 (14.2) | 9533 (11.6) |
| Negative | 50 934 (73.6) | 9358 (72.7) | 60 292 (73.4) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 3134 (4.5) | 573 (4.5) | 3707 (4.5) |
| Ki67 | |||
| Low | 16 797 (24.3) | 2681 (20.8) | 19 478 (23.7) |
| Intermediate | 5842 (8.4) | 951 (7.4) | 6793 (8.3) |
| High | 17 981 (26.0) | 3786 (29.4) | 21 767 (26.5) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 21 149 (30.6) | 4345 (33.8) | 25 494 (31.1) |
| Subtype | |||
| Luminal A | 23 861 (34.5) | 3670 (28.5) | 27 531 (33.5) |
| Luminal B | 12 525 (18.1) | 2654 (20.6) | 15 179 (18.5) |
| HER2+ HR+ | 5274 (7.6) | 1242 (9.7) | 6516 (7.9) |
| HER2+ HR– | 2384 (3.4) | 572 (4.4) | 2956 (3.6) |
| Triple-negative | 5175 (7.5) | 1117 (8.7) | 6292 (7.7) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 12 550 (18.1) | 2508 (19.5) | 15 058 (18.3) |
| Subtype (other definition) | |||
| Luminal A (NHG 1) | 11 555 (16.7) | 1551 (12.1) | 13 106 (16.0) |
| Luminal NHG 2 | 24 945 (36.0) | 4580 (35.6) | 29 525 (36.0) |
| Luminal B (NHG 3) | 7514 (10.9) | 1695 (13.2) | 9209 (11.2) |
| HER2+HR+ | 5274 (7.6) | 1242 (9.7) | 6516 (7.9) |
| HER2+ HR– | 2384 (3.4) | 572 (4.5) | 2956 (3.6) |
| Triple-negative | 5175 (7.5) | 1117 (8.7) | 6292 (7.7) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 4922 (7.1) | 1006 (7.8) | 5928 (7.2) |
| Nodal stage | |||
| N0 | 50 086 (72.4) | 7225 (56.1) | 57 311 (69.8) |
| N1 | 14 256 (20.6) | 4046 (31.4) | 18 302 (22.3) |
| N2 | 3180 (4.6) | 1039 (8.1) | 4219 (5.1) |
| N3 | 1322 (1.9) | 499 (3.9) | 1821 (2.2) |
| Missing | 383 (0.6) | 66 (0.5) | 449 (0.6) |
| > . | No SSI n = 69 227 . | SSI n = 12 875 . | Overall n = 82 102 . |
|---|---|---|---|
| Invasivity | |||
| Invasive | 61 589 (89.0) | 11 724 (91.1) | 73 313 (89.3) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 180 (0.3) | 39 (0.3) | 219 (0.3) |
| Tumour stage | |||
| T0 | 423 (0.6) | 72 (0.6) | 495 (0.6) |
| Tis | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| T1 | 39 075 (56.5) | 6313 (49.0) | 45 388 (55.3) |
| T2 | 18 137 (26.2) | 4266 (33.1) | 22 403 (27.3) |
| T3 | 2809 (4.1) | 782 (6.1) | 3591 (4.4) |
| T4 | 473 (0.7) | 151 (1.2) | 624 (0.8) |
| Unknown | 849 (1.2) | 179 (1.4) | 1028 (1.3) |
| Histological tumour type | |||
| NST | 47 159 (68.1) | 9012 (70.0) | 56 171 (68.4) |
| NST + lobular | 1250 (1.8) | 292 (2.3) | 1542 (1.9) |
| Lobular | 7803 (11.3) | 1575 (12.2) | 9378 (11.4) |
| Other invasive | 4500 (6.5) | 676 (5.3) | 5176 (6.3) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 1057 (1.5) | 208 (1.6) | 1265 (1.5) |
| NHG | |||
| 1 | 12 478 (18.0) | 1704 (13.2) | 14 182 (17.3) |
| 2 | 29 363 (42.4) | 5450 (42.3) | 34 813 (42.4) |
| 3 | 15 889 (23.0) | 3590 (27.9) | 19 479 (23.7) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 4039 (5.8) | 1019 (7.9) | 5058 (6.2) |
| ER | |||
| Positive | 52 522 (75.9) | 9743 (75.7) | 62 265 (75.8) |
| Negative | 8190 (11.8) | 1813 (14.1) | 10 003 (12.2) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 1057 (1.5) | 207 (1.6) | 1264 (1.5) |
| PR | |||
| Positive | 44 385 (64.1) | 8136 (63.2) | 52 521 (64.0) |
| Negative | 16 256 (23.5) | 3407 (26.5) | 19 663 (24.0) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 1128 (1.6) | 220 (1.7) | 1348 (1.6) |
| HER2 | |||
| Positive | 7701 (11.1) | 1832 (14.2) | 9533 (11.6) |
| Negative | 50 934 (73.6) | 9358 (72.7) | 60 292 (73.4) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 3134 (4.5) | 573 (4.5) | 3707 (4.5) |
| Ki67 | |||
| Low | 16 797 (24.3) | 2681 (20.8) | 19 478 (23.7) |
| Intermediate | 5842 (8.4) | 951 (7.4) | 6793 (8.3) |
| High | 17 981 (26.0) | 3786 (29.4) | 21 767 (26.5) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 21 149 (30.6) | 4345 (33.8) | 25 494 (31.1) |
| Subtype | |||
| Luminal A | 23 861 (34.5) | 3670 (28.5) | 27 531 (33.5) |
| Luminal B | 12 525 (18.1) | 2654 (20.6) | 15 179 (18.5) |
| HER2+ HR+ | 5274 (7.6) | 1242 (9.7) | 6516 (7.9) |
| HER2+ HR– | 2384 (3.4) | 572 (4.4) | 2956 (3.6) |
| Triple-negative | 5175 (7.5) | 1117 (8.7) | 6292 (7.7) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 12 550 (18.1) | 2508 (19.5) | 15 058 (18.3) |
| Subtype (other definition) | |||
| Luminal A (NHG 1) | 11 555 (16.7) | 1551 (12.1) | 13 106 (16.0) |
| Luminal NHG 2 | 24 945 (36.0) | 4580 (35.6) | 29 525 (36.0) |
| Luminal B (NHG 3) | 7514 (10.9) | 1695 (13.2) | 9209 (11.2) |
| HER2+HR+ | 5274 (7.6) | 1242 (9.7) | 6516 (7.9) |
| HER2+ HR– | 2384 (3.4) | 572 (4.5) | 2956 (3.6) |
| Triple-negative | 5175 (7.5) | 1117 (8.7) | 6292 (7.7) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 4922 (7.1) | 1006 (7.8) | 5928 (7.2) |
| Nodal stage | |||
| N0 | 50 086 (72.4) | 7225 (56.1) | 57 311 (69.8) |
| N1 | 14 256 (20.6) | 4046 (31.4) | 18 302 (22.3) |
| N2 | 3180 (4.6) | 1039 (8.1) | 4219 (5.1) |
| N3 | 1322 (1.9) | 499 (3.9) | 1821 (2.2) |
| Missing | 383 (0.6) | 66 (0.5) | 449 (0.6) |
Values are n (%). SSI, surgical site infection; Tis, carcinoma in situ; NST, no special type (former ductal); ER, oestrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NHG, Nottingham histological grade; Ki67, proliferation index.
Disease characteristics in a population-based cohort of 82 102 individuals with breast cancer diagnosed between 2008 and 2019
| > . | No SSI n = 69 227 . | SSI n = 12 875 . | Overall n = 82 102 . |
|---|---|---|---|
| Invasivity | |||
| Invasive | 61 589 (89.0) | 11 724 (91.1) | 73 313 (89.3) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 180 (0.3) | 39 (0.3) | 219 (0.3) |
| Tumour stage | |||
| T0 | 423 (0.6) | 72 (0.6) | 495 (0.6) |
| Tis | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| T1 | 39 075 (56.5) | 6313 (49.0) | 45 388 (55.3) |
| T2 | 18 137 (26.2) | 4266 (33.1) | 22 403 (27.3) |
| T3 | 2809 (4.1) | 782 (6.1) | 3591 (4.4) |
| T4 | 473 (0.7) | 151 (1.2) | 624 (0.8) |
| Unknown | 849 (1.2) | 179 (1.4) | 1028 (1.3) |
| Histological tumour type | |||
| NST | 47 159 (68.1) | 9012 (70.0) | 56 171 (68.4) |
| NST + lobular | 1250 (1.8) | 292 (2.3) | 1542 (1.9) |
| Lobular | 7803 (11.3) | 1575 (12.2) | 9378 (11.4) |
| Other invasive | 4500 (6.5) | 676 (5.3) | 5176 (6.3) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 1057 (1.5) | 208 (1.6) | 1265 (1.5) |
| NHG | |||
| 1 | 12 478 (18.0) | 1704 (13.2) | 14 182 (17.3) |
| 2 | 29 363 (42.4) | 5450 (42.3) | 34 813 (42.4) |
| 3 | 15 889 (23.0) | 3590 (27.9) | 19 479 (23.7) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 4039 (5.8) | 1019 (7.9) | 5058 (6.2) |
| ER | |||
| Positive | 52 522 (75.9) | 9743 (75.7) | 62 265 (75.8) |
| Negative | 8190 (11.8) | 1813 (14.1) | 10 003 (12.2) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 1057 (1.5) | 207 (1.6) | 1264 (1.5) |
| PR | |||
| Positive | 44 385 (64.1) | 8136 (63.2) | 52 521 (64.0) |
| Negative | 16 256 (23.5) | 3407 (26.5) | 19 663 (24.0) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 1128 (1.6) | 220 (1.7) | 1348 (1.6) |
| HER2 | |||
| Positive | 7701 (11.1) | 1832 (14.2) | 9533 (11.6) |
| Negative | 50 934 (73.6) | 9358 (72.7) | 60 292 (73.4) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 3134 (4.5) | 573 (4.5) | 3707 (4.5) |
| Ki67 | |||
| Low | 16 797 (24.3) | 2681 (20.8) | 19 478 (23.7) |
| Intermediate | 5842 (8.4) | 951 (7.4) | 6793 (8.3) |
| High | 17 981 (26.0) | 3786 (29.4) | 21 767 (26.5) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 21 149 (30.6) | 4345 (33.8) | 25 494 (31.1) |
| Subtype | |||
| Luminal A | 23 861 (34.5) | 3670 (28.5) | 27 531 (33.5) |
| Luminal B | 12 525 (18.1) | 2654 (20.6) | 15 179 (18.5) |
| HER2+ HR+ | 5274 (7.6) | 1242 (9.7) | 6516 (7.9) |
| HER2+ HR– | 2384 (3.4) | 572 (4.4) | 2956 (3.6) |
| Triple-negative | 5175 (7.5) | 1117 (8.7) | 6292 (7.7) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 12 550 (18.1) | 2508 (19.5) | 15 058 (18.3) |
| Subtype (other definition) | |||
| Luminal A (NHG 1) | 11 555 (16.7) | 1551 (12.1) | 13 106 (16.0) |
| Luminal NHG 2 | 24 945 (36.0) | 4580 (35.6) | 29 525 (36.0) |
| Luminal B (NHG 3) | 7514 (10.9) | 1695 (13.2) | 9209 (11.2) |
| HER2+HR+ | 5274 (7.6) | 1242 (9.7) | 6516 (7.9) |
| HER2+ HR– | 2384 (3.4) | 572 (4.5) | 2956 (3.6) |
| Triple-negative | 5175 (7.5) | 1117 (8.7) | 6292 (7.7) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 4922 (7.1) | 1006 (7.8) | 5928 (7.2) |
| Nodal stage | |||
| N0 | 50 086 (72.4) | 7225 (56.1) | 57 311 (69.8) |
| N1 | 14 256 (20.6) | 4046 (31.4) | 18 302 (22.3) |
| N2 | 3180 (4.6) | 1039 (8.1) | 4219 (5.1) |
| N3 | 1322 (1.9) | 499 (3.9) | 1821 (2.2) |
| Missing | 383 (0.6) | 66 (0.5) | 449 (0.6) |
| > . | No SSI n = 69 227 . | SSI n = 12 875 . | Overall n = 82 102 . |
|---|---|---|---|
| Invasivity | |||
| Invasive | 61 589 (89.0) | 11 724 (91.1) | 73 313 (89.3) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 180 (0.3) | 39 (0.3) | 219 (0.3) |
| Tumour stage | |||
| T0 | 423 (0.6) | 72 (0.6) | 495 (0.6) |
| Tis | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| T1 | 39 075 (56.5) | 6313 (49.0) | 45 388 (55.3) |
| T2 | 18 137 (26.2) | 4266 (33.1) | 22 403 (27.3) |
| T3 | 2809 (4.1) | 782 (6.1) | 3591 (4.4) |
| T4 | 473 (0.7) | 151 (1.2) | 624 (0.8) |
| Unknown | 849 (1.2) | 179 (1.4) | 1028 (1.3) |
| Histological tumour type | |||
| NST | 47 159 (68.1) | 9012 (70.0) | 56 171 (68.4) |
| NST + lobular | 1250 (1.8) | 292 (2.3) | 1542 (1.9) |
| Lobular | 7803 (11.3) | 1575 (12.2) | 9378 (11.4) |
| Other invasive | 4500 (6.5) | 676 (5.3) | 5176 (6.3) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 1057 (1.5) | 208 (1.6) | 1265 (1.5) |
| NHG | |||
| 1 | 12 478 (18.0) | 1704 (13.2) | 14 182 (17.3) |
| 2 | 29 363 (42.4) | 5450 (42.3) | 34 813 (42.4) |
| 3 | 15 889 (23.0) | 3590 (27.9) | 19 479 (23.7) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 4039 (5.8) | 1019 (7.9) | 5058 (6.2) |
| ER | |||
| Positive | 52 522 (75.9) | 9743 (75.7) | 62 265 (75.8) |
| Negative | 8190 (11.8) | 1813 (14.1) | 10 003 (12.2) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 1057 (1.5) | 207 (1.6) | 1264 (1.5) |
| PR | |||
| Positive | 44 385 (64.1) | 8136 (63.2) | 52 521 (64.0) |
| Negative | 16 256 (23.5) | 3407 (26.5) | 19 663 (24.0) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 1128 (1.6) | 220 (1.7) | 1348 (1.6) |
| HER2 | |||
| Positive | 7701 (11.1) | 1832 (14.2) | 9533 (11.6) |
| Negative | 50 934 (73.6) | 9358 (72.7) | 60 292 (73.4) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 3134 (4.5) | 573 (4.5) | 3707 (4.5) |
| Ki67 | |||
| Low | 16 797 (24.3) | 2681 (20.8) | 19 478 (23.7) |
| Intermediate | 5842 (8.4) | 951 (7.4) | 6793 (8.3) |
| High | 17 981 (26.0) | 3786 (29.4) | 21 767 (26.5) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 21 149 (30.6) | 4345 (33.8) | 25 494 (31.1) |
| Subtype | |||
| Luminal A | 23 861 (34.5) | 3670 (28.5) | 27 531 (33.5) |
| Luminal B | 12 525 (18.1) | 2654 (20.6) | 15 179 (18.5) |
| HER2+ HR+ | 5274 (7.6) | 1242 (9.7) | 6516 (7.9) |
| HER2+ HR– | 2384 (3.4) | 572 (4.4) | 2956 (3.6) |
| Triple-negative | 5175 (7.5) | 1117 (8.7) | 6292 (7.7) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 12 550 (18.1) | 2508 (19.5) | 15 058 (18.3) |
| Subtype (other definition) | |||
| Luminal A (NHG 1) | 11 555 (16.7) | 1551 (12.1) | 13 106 (16.0) |
| Luminal NHG 2 | 24 945 (36.0) | 4580 (35.6) | 29 525 (36.0) |
| Luminal B (NHG 3) | 7514 (10.9) | 1695 (13.2) | 9209 (11.2) |
| HER2+HR+ | 5274 (7.6) | 1242 (9.7) | 6516 (7.9) |
| HER2+ HR– | 2384 (3.4) | 572 (4.5) | 2956 (3.6) |
| Triple-negative | 5175 (7.5) | 1117 (8.7) | 6292 (7.7) |
| In situ | 7458 (10.8) | 1112 (8.6) | 8570 (10.4) |
| Missing | 4922 (7.1) | 1006 (7.8) | 5928 (7.2) |
| Nodal stage | |||
| N0 | 50 086 (72.4) | 7225 (56.1) | 57 311 (69.8) |
| N1 | 14 256 (20.6) | 4046 (31.4) | 18 302 (22.3) |
| N2 | 3180 (4.6) | 1039 (8.1) | 4219 (5.1) |
| N3 | 1322 (1.9) | 499 (3.9) | 1821 (2.2) |
| Missing | 383 (0.6) | 66 (0.5) | 449 (0.6) |
Values are n (%). SSI, surgical site infection; Tis, carcinoma in situ; NST, no special type (former ductal); ER, oestrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NHG, Nottingham histological grade; Ki67, proliferation index.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
